All In Biotech

Free tool

FAERS Monitor: Yartemlea

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761152 or its brand name (Yartemlea, Narsoplimab-Wuug). Reports on generic versions are filed under their own applications.

Reports

21

Serious

21

100% of reports

Hospitalization

8

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • thrombotic microangiopathy5
  • drug ineffective4
  • thrombocytopenia3
  • acute graft versus host disease in skin2
  • acute kidney injury2
  • cytopenia2
  • disease recurrence2
  • gastrointestinal haemorrhage2
  • hypertension2
  • hypervolaemia2
  • respiratory failure2
  • acute respiratory distress syndrome1
  • acute respiratory failure1
  • allogenic stem cell transplantation1
  • anaemia vitamin b12 deficiency1

Reports by year received

View as table
YearReports
20213
20225
20234
20252
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
allogenic stem cell transplantation16385.8937.01,585
anaemia vitamin b12 deficiency12029.5299.1505
acute graft versus host disease in skin2725.2194.0812
thrombotic microangiopathySignal5514.1239.22,073
hypervolaemia2405.5108.5453
cytopenia2163.643.8181
acute respiratory distress syndrome156.68.413
acute respiratory failure152.17.712
disease recurrence242.111.345
respiratory failure227.57.328
thrombocytopeniaSignal326.99.451
gastrointestinal haemorrhage224.06.424
acute kidney injury213.13.512
hypertension29.52.58
drug ineffective43.01.34

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.